- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07387198
Neoadjuvante therapie (Tx) voor Merkelcelcarcinoom met de PD-1-remmer Cemiplimab (NeoMatryx)
Neoadjuvante Therapie (Tx) voor Merkelcelcarcinoom met de PD-1-remmer Cemiplimab - Een gerandomiseerde, dubbelblinde, placebo-gecontroleerde, niet-vergelijkende fase II-studie
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
Studie Overzicht
Toestand
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Michelle Tez
- E-mail: tez.michelle@ikf-khnw.de
Studie Contact Back-up
- Naam: Ralf Gutzmer, Prof. Dr. med.
- E-mail: Ralf.Gutzmer@Muehlenkreiskliniken.de
Studie Locaties
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Duitsland, 69120
- Werving
- Nationales Centrum für Tumorerkrankungen
-
Contact:
- Jessica Hassel, Prof. Dr.
-
Mannheim, Baden-Wurttemberg, Duitsland, 68161
- Werving
- Universitätsklinikum Mannheim
-
Contact:
- Jochen Utikal, Prof. Dr.
-
Tübingen, Baden-Wurttemberg, Duitsland, 72076
- Werving
- Universitätsklinikum Tübingen
-
Contact:
- Ulrike Leiter-Stöppke, Prof. Dr.
-
-
Bavaria
-
Regensburg, Bavaria, Duitsland, 93053
- Werving
- Universitätsklinikum Regensburg
-
Contact:
- Sebastian Haferkamp, Prof. Dr.
-
Würzburg, Bavaria, Duitsland, 97080
- Werving
- Universitätsklinikum Würzburg
-
Contact:
- Anja Gieserich, Dr.
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Duitsland, 20246
- Werving
- Universitätsklinikum Hamburg-Eppendorf
-
Contact:
- Christoffer Gebhardt, Prof. Dr.
-
-
Hesse
-
Frankfurt am Main, Hesse, Duitsland, 60590
- Werving
- Universitätsklinikum Frankfurt
-
Contact:
- Bastian Schilling, Prof. Dr.
-
-
North Rhine-Westphalia
-
Bielefeld, North Rhine-Westphalia, Duitsland, 33647
- Werving
- Klinikum Bielefeld
-
Contact:
- Selma Ugurel, Prof. Dr.
-
Essen, North Rhine-Westphalia, Duitsland, 45147
- Werving
- Universitätsklinikum Essen
-
Contact:
- Dirk Schadendorf, Prof. Dr.
-
Minden, North Rhine-Westphalia, Duitsland, 32429
- Nog niet aan het werven
- Johannes Wesling Klinikum Minden
-
Contact:
- Ralf Gutzmer, Prof. Dr.
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Duitsland, 55131
- Werving
- Universitätsmedizin Mainz
-
Contact:
- Stefan Grabbe, Prof. Dr.
-
-
Thuringia
-
Erfurt, Thuringia, Duitsland, 99089
- Werving
- Helios Klinikum Erfurt
-
Contact:
- Rudolph Herbst, Prof. Dr.
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria
-
Patient has signed informed written consent.
-
Patients is 18 years and older at time of signing of written informed consent
-
Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes biopsy still pending.
-
Patient has ECOG performance status 0-2.
-
Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters.
- Absolute number of neutrophils ≥ 1.5 x 109/L
- Platelets ≥ 75 x 109/L
- Hemoglobin ≥ 9 g/dL
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
- AST (SGOT) and ALT (SGPT) ≤ 3x ULN
- AP ≤ 2.5x ULN
- Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL/min
-
Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.
-
Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).
Exclusion criteria
-
Patient has prior sentinel lymph node removal for the current MCC.
-
Patients received prior treatment with immunotherapy (such as PD-1/PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. investigational therapies)
-
Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not.
-
Patient had prior organ transplantation including allogenic stem-cell transplantation.
-
Patient receives immunosuppressive concomitant medication, EXCEPT for the following:
i. Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection).
ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.
iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
-
Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.
-
Patient has active autoimmune or inflammatory disorders.
-
Patient has history of interstitial lung disease.
-
Patient has active infection requiring systemic therapy.
-
Patient has Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency.
NOTE: Patients are eligible if:
- Patients have controlled HIV infection with CD4 counts is > 350 cells/μL and viral load is undetectable [HIV RNA PCR]. Patients with controlled HIV infection must be monitored per local standards during the trial.
- Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load [HBV DNA PCR]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab.
- Patients positive for HCV antibody have controlled HCV infection with undetectable viral load [HCV RNA PCR].
-
Patent received vaccination with any live vaccine (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial
-
Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment.
-
Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results.
-
Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
-
Patient is legally incapacitated or has limited legal capacity
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A (Cemiplimab)
2 cycles of Cemiplimab (350 mg, i.v., Q3W) followed by sentinel lymph node biopsy |
Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
Andere namen:
|
|
Placebo-vergelijker: Arm B (placebo)
2 cycles of placebo followed by sentinel lymph node biopsy |
Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Nodal micrometastases-free rate
Tijdsspanne: up to 36 months
|
rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy |
up to 36 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Recurrence-free survival
Tijdsspanne: up to 66 months
|
time from randomization until date of the first of the following events: MCC recurrence, and MCC-related death |
up to 66 months
|
|
Time to recurrence
Tijdsspanne: up to 66 months
|
defined as time from randomization until date of first MCC recurrence |
up to 66 months
|
|
Overall survival
Tijdsspanne: up to 66 months
|
time from randomization until date of death from any cause |
up to 66 months
|
|
Quality of life using FCRI-SF questionnaire
Tijdsspanne: up to 66 months
|
Quality of life determined using the FCRI-SF questionnaire |
up to 66 months
|
|
Safety (AEs and SAEs)
Tijdsspanne: up to 66 months
|
incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5 |
up to 66 months
|
|
Disease specific survival
Tijdsspanne: up to 66 months
|
time from randomization until date of MCC-related death |
up to 66 months
|
|
Quality of life using the mFACT-M questionnaire
Tijdsspanne: up to 66 months
|
Quality of life determined using the mFACT-M questionnaire |
up to 66 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Investigation of prognostic and predictive biomarkers to estimate the risk of lymph node metastases and signs of immune activation in the sentinel lymph nodes
Tijdsspanne: up to 66 months
|
Biosamples will be used to determine the correlation of identified biomarkers with clinical outcome, i.e., nodal metastases-free rate, RFS, OS |
up to 66 months
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie directeur: Salah Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH
- Hoofdonderzoeker: Ralf Gutzmer, Prof. Dr. med., Johannes Wesling Klinikum Minden
- Hoofdonderzoeker: Juergen C. Becker, Prof. Dr. Dr., Translational Skin Cancer Research University Duisburg-Essen, Germany
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Infecties
- Virusziekten
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- DNA-virusinfecties
- Huidziektes
- Carcinoom
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Neuro-endocriene tumoren
- Tumorvirusinfecties
- Polyomavirus-infecties
- Carcinoom, neuro-endocrien
- Huid- en bindweefselaandoeningen
- Huidneoplasmata
- Carcinoom, Merkelcel
- cemiplimab
Andere studie-ID-nummers
- NeoMatryx
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .